International
The Morning Science

What science found today

‹
 

Research2 sources

Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy

Medical Xpress ·

Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy

The Brief · written from 2 sources

  • Erasca reported data on its KRAS-targeted drug in pancreatic cancer, adding pressure on Revolution Medicines' drug Rasonque, according to BioPharma Dive.
  • BioPharma Dive says Rasonque is already off to one of the best oncology launches in history, but certain limitations leave room for rivals such as Erasca, which is nearing the start of a Phase 3 trial.
  • New Phase I/II results reported by Medical Xpress show daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with metastatic pancreatic cancer.

Why it matters

Competition is forming around KRAS-targeted treatment for pancreatic cancer, and the limitations of the leading drug may shape which approaches reach later-stage trials.

Who’s affected

  • oncologists and pancreatic cancer researchers
  • patients with metastatic pancreatic cancer

Daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a Phase I/II clinical trial.

Timeline

  1. Erasca data reported, adding pressure on Revolution Medicines' Rasonque

  2. Phase I/II results show daraxonrasib plus chemotherapy shrank tumors in metastatic pancreatic cancer

  3. BioPharma Dive - Latest News

    Erasca data add to pressure facing Revolution’s breakthrough cancer drug

  4. Medical Xpress - latest medical and health news stories

    Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy

Full coverage · 2 sources

How do you feel about this?

0 Comments

    Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy – The Morning Science